Amarin Corporation

Amarin Corporation EPS

The Earnings per Share (EPS) of Amarin Corporation (AMRN) as of Nov 4, 2026 is -1.87 USD. In the previous year, Earnings per Share (EPS) was -4.00 USD — a change of -53.37% (higher).

EPS

-1.87USD

YoY

-53.37%

Last updated:

Earnings per Share (EPS) of Amarin Corporation is 2025 -1.87 USD. Earnings per Share (EPS) of Amarin Corporation was 2024 -4.00 USD. It decreases by -53.37% higher compared to the previous year.

The Amarin Corporation EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
-5.27 USD
Jan 1, 2023
-2.89 USD
Jan 1, 2024
-4.00 USD
Jan 1, 2025
-1.87 USD
Jan 1, 2026 (e)
-0.60 USD
Jan 1, 2027 (e)
-0.34 USD
Jan 1, 2028 (e)
-0.44 USD
Jan 1, 2029 (e)
0.19 USD
The Amarin Corporation EPS history
YEAREPSYoY
est0.19USD-142.86%
est-0.44USD+28.83%
est-0.34USD-42.55%
est-0.60USD-67.89%
-1.87USD-53.37%
-4.00USD+38.20%
-2.89USD-45.06%
-5.27USD-1,469.15%
0.38USD-142.64%
-0.90USD-31.75%
-1.32USD-82.16%
-7.41USD+55.76%
-4.76USD-25.81%
-6.41USD-48.96%
-12.57USD+94.67%
-6.46USD-66.12%
-19.06USD-20.00%
-23.82USD+133.37%
-10.21USD-69.01%
-32.94USD+846.65%
-3.48USD-85.19%
-23.49USD+760.08%
-2.73USD-95.41%
-59.50USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Earnings per Share (EPS) of Amarin Corporation is -1.87 USD in 2025.

Earnings per Share (EPS) of Amarin Corporation changed from -4.00 USD to -1.87 USD, representing a -53.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Amarin Corporation

All Key Metrics — Amarin Corporation